As Lilly Eli & Co (LLY) Shares Rose, Holder Sector Gamma As Lowered Stake by $17.98 Million; As Idexx Laboratories (IDXX) Stock Value Declined, Bank Of Hawaii Has Lowered Holding

Eli Lilly and Company (NYSE:LLY) Logo

Bank Of Hawaii decreased its stake in Idexx Laboratories Inc (IDXX) by 26.29% based on its latest 2018Q3 regulatory filing with the SEC. Bank Of Hawaii sold 2,390 shares as the company’s stock declined 20.36% with the market. The institutional investor held 6,700 shares of the health care company at the end of 2018Q3, valued at $1.67M, down from 9,090 at the end of the previous reported quarter. Bank Of Hawaii who had been investing in Idexx Laboratories Inc for a number of months, seems to be less bullish one the $18.14 billion market cap company. The stock increased 0.42% or $0.89 during the last trading session, reaching $210.39. About 382,737 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 22.67% since February 14, 2018 and is uptrending. It has outperformed by 22.67% the S&P500.

Sector Gamma As decreased its stake in Lilly Eli & Co (LLY) by 92.49% based on its latest 2018Q3 regulatory filing with the SEC. Sector Gamma As sold 167,991 shares as the company’s stock rose 7.21% while stock markets declined. The institutional investor held 13,650 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $1.47 million, down from 181,641 at the end of the previous reported quarter. Sector Gamma As who had been investing in Lilly Eli & Co for a number of months, seems to be less bullish one the $120.69B market cap company. The stock increased 0.13% or $0.16 during the last trading session, reaching $119.65. About 12.74 million shares traded or 137.35% up from the average. Eli Lilly and Company (NYSE:LLY) has risen 32.86% since February 14, 2018 and is uptrending. It has outperformed by 32.86% the S&P500. Some Historical LLY News: 08/05/2018 – J&J’s Janssen: FDA Approval Marks the Fifth Indication for Darzalex, Which Is the First CD38-Directed Antibody to Be Approved Anywhere; 04/04/2018 – ELI LILLY AND CO – AN ONGOING PHASE 3 TRIAL IN ADVANCED UROTHELIAL CARCINOMA HAS MET ITS PRIMARY ENDPOINT OF PFS, AND OS DATA EXPECTED IN H1 2018; 30/04/2018 – LEENA GANDHI TO LEAD LILLY IMMUNO-ONCOLOGY MEDICAL DEVELOPMENT; 14/05/2018 – Eli Lilly: AurKa Shareholders Eligible to Receive Up to $465 Million in Milestone Payments; 24/04/2018 – Eli Lilly Sees FY Rev $23.7B-$24.2B; 15/04/2018 – ASTRAZENECA- TRIAL COMPARED LYNPARZA WITH CHEMOTHERAPY FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER, MET PRIMARY ENDPOINT; 22/03/2018 – MI House GOP: Education panel approves Rep. Lilly’s new teacher prep bill; 13/03/2018 – FDA: New Drug Application (NDA): 022307 Company: ELI LILLY AND CO; 24/04/2018 – Eli Lilly Raises 2018 Profit View After Quarterly Earnings, Sales Beat Expectations — MarketWatch; 13/04/2018 – OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER…

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Seekingalpha.com which released: “Eli Lilly Is An Attractive Buy For 2018 – Seeking Alpha” on August 11, 2018, also Streetinsider.com with their article: “Pfizer (PFE), Lilly (LLY) Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain – StreetInsider.com” published on January 29, 2019, Forbes.com published: “Elanco Animal Health Makes Stellar Debut – Forbes” on September 24, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Benzinga.com and their article: “JPMorgan Resumes Coverage Of Eli Lilly (NYSE:LLY): ‘One Of The Best-Positioned Names In Our Group’ – Benzinga” published on September 26, 2018 as well as 247Wallst.com‘s news article titled: “Short Interest Spikes in a Couple Major Pharma Stocks – 24/7 Wall St.” with publication date: January 28, 2019.

Since August 15, 2018, it had 0 insider buys, and 26 sales for $285.41 million activity. On Thursday, January 31 Zulueta Alfonso G sold $480,000 worth of Eli Lilly and Company (NYSE:LLY) or 4,000 shares. Shares for $2.82M were sold by O’Neill Myles on Monday, December 10. Zakrowski Donald A had sold 600 shares worth $63,342 on Tuesday, September 4.

Among 25 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 0 Sell and 12 Hold. Therefore 52% are positive. Eli Lilly and Company had 124 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Eli Lilly and Company (NYSE:LLY) earned “Underperform” rating by Credit Suisse on Wednesday, July 25. The firm has “Hold” rating by Societe Generale given on Wednesday, April 6. The rating was maintained by Morgan Stanley on Tuesday, November 21 with “Equal-Weight”. The stock of Eli Lilly and Company (NYSE:LLY) has “Buy” rating given on Thursday, June 22 by Jefferies. The stock of Eli Lilly and Company (NYSE:LLY) earned “Buy” rating by Jefferies on Friday, April 13. The stock of Eli Lilly and Company (NYSE:LLY) has “Market Perform” rating given on Wednesday, July 26 by Leerink Swann. The stock of Eli Lilly and Company (NYSE:LLY) has “Overweight” rating given on Friday, April 7 by Barclays Capital. The rating was upgraded by Credit Suisse to “Neutral” on Wednesday, October 31. The firm has “Buy” rating by Argus Research given on Tuesday, August 2. The firm earned “Neutral” rating on Tuesday, July 17 by Bank of America.

Investors sentiment increased to 0.98 in Q3 2018. Its up 0.14, from 0.84 in 2018Q2. It increased, as 37 investors sold LLY shares while 399 reduced holdings. 141 funds opened positions while 286 raised stakes. 794.28 million shares or 1.80% less from 808.82 million shares in 2018Q2 were reported. Sector Gamma As holds 0% or 32 shares in its portfolio. Lincoln National reported 4,034 shares. Moreover, Dnb Asset Mngmt As has 0% invested in Eli Lilly and Company (NYSE:LLY) for 935,406 shares. Meiji Yasuda Life Ins owns 0.21% invested in Eli Lilly and Company (NYSE:LLY) for 15,537 shares. Raymond James Na accumulated 0.27% or 40,888 shares. Invesco invested in 0.26% or 7.68 million shares. Exane Derivatives stated it has 11,964 shares. Argent has 7,998 shares for 0.1% of their portfolio. Jaffetilchin Inv Ptnrs Lc holds 2,475 shares. Van Eck Associate Corporation invested in 394,153 shares or 0.21% of the stock. 2,644 were reported by Evergreen Capital Management. Mirae Asset Global Invests Ltd reported 83,405 shares or 0.07% of all its holdings. Tiverton Asset Management Ltd Liability Co reported 13,590 shares. Lilly Endowment Incorporated reported 119.40 million shares or 100% of all its holdings. Barometer Capital, Ontario – Canada-based fund reported 158,845 shares.

Sector Gamma As, which manages about $637.80M US Long portfolio, upped its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 12,937 shares to 45,437 shares, valued at $3.98 million in 2018Q3, according to the filing. It also increased its holding in Shire Plc (NASDAQ:SHPG) by 33,431 shares in the quarter, for a total of 205,256 shares, and has risen its stake in Bio Rad Labs Inc (NYSE:BIO).

More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Seekingalpha.com which released: “Well-Healed IDEXX Laboratories – Seeking Alpha” on March 27, 2017, also Nasdaq.com with their article: “Friday 2/8 Insider Buying Report: ADM, IDXX – Nasdaq” published on February 08, 2019, Nasdaq.com published: “First Week of IDXX March 15th Options Trading – Nasdaq” on January 25, 2019. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Nasdaq.com and their article: “IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss – Nasdaq” published on October 31, 2017 as well as Seekingalpha.com‘s news article titled: “Canaccord bullish on medical diagnostic firms – Seeking Alpha” with publication date: September 14, 2018.

Since August 21, 2018, it had 1 buying transaction, and 8 sales for $25.31 million activity. Lane Michael sold $1.44M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Tuesday, August 21. Shares for $682,992 were sold by HENDERSON REBECCA M on Tuesday, November 27. Kingsley Lawrence D bought $501,875 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Tuesday, February 5. 30,000 shares valued at $7.37M were sold by AYERS JONATHAN W on Tuesday, August 21. Shares for $666,823 were sold by Studer Jacqueline.

Bank Of Hawaii, which manages about $1.30 billion and $1.30B US Long portfolio, upped its stake in Chipotle Mexican Grill (NYSE:CMG) by 900 shares to 1,640 shares, valued at $745,000 in 2018Q3, according to the filing. It also increased its holding in Texas Instruments Inc (NASDAQ:TXN) by 4,247 shares in the quarter, for a total of 34,610 shares, and has risen its stake in Allison Transmission Holding (NYSE:ALSN).

Among 11 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. IDEXX Laboratories had 35 analyst reports since July 24, 2015 according to SRatingsIntel. On Tuesday, July 10 the stock rating was maintained by Stifel Nicolaus with “Buy”. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Tuesday, June 13 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Monday, March 21 with “Buy”. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Monday, May 7 with “Buy” rating. The stock has “Neutral” rating by Bank of America on Thursday, September 29. The firm earned “Outperform” rating on Friday, June 1 by Credit Suisse. The company was upgraded on Friday, July 24 by Feltl & Co. Stifel Nicolaus maintained the shares of IDXX in report on Thursday, August 13 with “Buy” rating. The firm has “Buy” rating given on Monday, August 21 by Stifel Nicolaus. Credit Suisse maintained it with “Outperform” rating and $85 target in Wednesday, April 13 report.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart